Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1962 1
1964 1
1965 3
1966 2
1967 1
1968 5
1971 4
1973 2
1975 1
1976 4
1977 4
1978 8
1979 2
1980 4
1981 3
1982 4
1983 3
1984 7
1985 6
1986 9
1987 10
1988 12
1989 10
1990 8
1991 15
1992 17
1993 14
1994 14
1995 19
1996 22
1997 14
1998 32
1999 22
2000 13
2001 26
2002 11
2003 20
2004 11
2005 13
2006 14
2007 11
2008 8
2009 11
2010 4
2011 11
2012 7
2013 5
2014 12
2015 12
2016 15
2017 12
2018 30
2019 16
2020 24
2021 24
2022 20
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

593 results

Results by year

Filters applied: . Clear all
Page 1
Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL.
Miyazaki K, Sakai R, Iwaki N, Yamamoto G, Murayama K, Nishikori M, Sunami K, Yoshida I, Yano H, Takahashi N, Okamoto A, Munemoto S, Sawazaki A, Suehiro Y, Fukuhara N, Wake A, Arai A, Masaki Y, Toyama K, Yokoyama A, Tsunemine H, Hasegawa Y, Matsumoto K, Yamada T, Nishimura Y, Tamaru S, Asano N, Miyawaki K, Izutsu K, Kinoshita T, Suzuki R, Ohshima K, Kato K, Katayama N, Yamaguchi M. Miyazaki K, et al. Among authors: yoshida i. Cancer Sci. 2023 Jun;114(6):2689-2691. doi: 10.1111/cas.15784. Epub 2023 Mar 16. Cancer Sci. 2023. PMID: 36929591 Free PMC article. Clinical Trial. No abstract available.
DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study.
Miyazaki K, Asano N, Yamada T, Miyawaki K, Sakai R, Igarashi T, Nishikori M, Ohata K, Sunami K, Yoshida I, Yamamoto G, Takahashi N, Okamoto M, Yano H, Nishimura Y, Tamaru S, Nishikawa M, Izutsu K, Kinoshita T, Suzumiya J, Ohshima K, Kato K, Katayama N, Yamaguchi M. Miyazaki K, et al. Among authors: yoshida i. Haematologica. 2020 Sep 1;105(9):2308-2315. doi: 10.3324/haematol.2019.231076. Haematologica. 2020. PMID: 33054055 Free PMC article. Clinical Trial.
[3-Methylcrotonyl-CoA carboxylase deficiency].
Yoshida I. Yoshida I. Ryoikibetsu Shokogun Shirizu. 1998;(18 Pt 1):284-7. Ryoikibetsu Shokogun Shirizu. 1998. PMID: 9590048 Review. Japanese. No abstract available.
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion.
Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IATM, Datir R, Collier DA, Albecka A, Singh S, Pandey R, Brown J, Zhou J, Goonawardane N, Mishra S, Whittaker C, Mellan T, Marwal R, Datta M, Sengupta S, Ponnusamy K, Radhakrishnan VS, Abdullahi A, Charles O, Chattopadhyay P, Devi P, Caputo D, Peacock T, Wattal C, Goel N, Satwik A, Vaishya R, Agarwal M; Indian SARS-CoV-2 Genomics Consortium (INSACOG); Genotype to Phenotype Japan (G2P-Japan) Consortium; CITIID-NIHR BioResource COVID-19 Collaboration; Mavousian A, Lee JH, Bassi J, Silacci-Fegni C, Saliba C, Pinto D, Irie T, Yoshida I, Hamilton WL, Sato K, Bhatt S, Flaxman S, James LC, Corti D, Piccoli L, Barclay WS, Rakshit P, Agrawal A, Gupta RK. Mlcochova P, et al. Among authors: yoshida i. Nature. 2021 Nov;599(7883):114-119. doi: 10.1038/s41586-021-03944-y. Epub 2021 Sep 6. Nature. 2021. PMID: 34488225 Free PMC article.
[Reye's syndrome].
Yoshida I. Yoshida I. Nihon Rinsho. 2000 Nov;58(11):2261-5. Nihon Rinsho. 2000. PMID: 11225315 Review. Japanese.
[3-Hydroxy-3-methylglutaryl-CoA-lyase deficiency].
Yoshida I. Yoshida I. Ryoikibetsu Shokogun Shirizu. 1998;(18 Pt 1):299-304. Ryoikibetsu Shokogun Shirizu. 1998. PMID: 9590052 Review. Japanese. No abstract available.
Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study.
Urata T, Naoi Y, Jiang A, Boyle M, Sunami K, Imai T, Nawa Y, Hiramatsu Y, Yamamoto K, Fujii S, Yoshida I, Yano T, Chijimatsu R, Murakami H, Ikeuchi K, Kobayashi H, Tani K, Ujiie H, Inoue H, Tomida S, Yamamoto A, Kondo T, Fujiwara H, Asada N, Nishimori H, Fujii K, Fujii N, Matsuoka KI, Sawada K, Momose S, Tamaru JI, Nishikori A, Sato Y, Yoshino T, Maeda Y, Scott DW, Ennishi D. Urata T, et al. Among authors: yoshida i. Blood Adv. 2023 Dec 26;7(24):7459-7470. doi: 10.1182/bloodadvances.2023010402. Blood Adv. 2023. PMID: 37552496 Free PMC article.
Head Injury Assessment in the Elite Level Rugby Union in Japan: Review of 3 Seasons.
Tajima T, Ota O, Nagayama M, Takahashi M, Yamada M, Ishiyama N, Yoshida I, Takemura M, Hara K, Akama T, Mitsumori N, Higashihara J, Toyama Y, Furuya M, Chosa E, Nakamura A. Tajima T, et al. Among authors: yoshida i. Int J Sports Med. 2022 Sep;43(10):889-894. doi: 10.1055/a-1810-6509. Epub 2022 Jun 7. Int J Sports Med. 2022. PMID: 35672000 Review.
593 results